Roberts Acquires Stanate Rights

7 August 1994

- Roberts Pharmaceutical has acquired exclusive worldwide rights to Stanate (SnMP), a new drug for the treatment of neonatal jaundice, from Rockefeller University in the USA. The drug is an effective inhibitor of bilirubin production in the liver. Accumulation of bilirubin does not occur in Stanate-treated patients and during such treatment infantile enzyme systems are allowed to mature and take over the normal elimination of bilirubin, said Roberts. Stanate is in Phase III testing and only one dose is usually needed to counter the condition.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight